Abstract
Th2 immunity and allergic immune surveillance play critical roles in host responses to pathogens, parasites and allergens. Numerous studies have reported significant links between Th2 responses and cancer, including insights into the functions of IgE antibodies and associated effector cells in both antitumour immune surveillance and therapy. The interdisciplinary field of AllergoOncology was given Task Force status by the European Academy of Allergy and Clinical Immunology in 2014. Affiliated expert groups focus on the interface between allergic responses and cancer, applied to immune surveillance, immunomodulation and the functions of IgE-mediated immune responses against cancer, to derive novel insights into more effective treatments. Coincident with rapid expansion in clinical application of cancer immunotherapies, here we review the current state-of-the-art and future translational opportunities, as well as challenges in this relatively new field. Recent developments include improved understanding of Th2 antibodies, intratumoral innate allergy effector cells and mediators, IgE-mediated tumour antigen cross-presentation by dendritic cells, as well as immunotherapeutic strategies such as vaccines and recombinant antibodies, and finally, the management of allergy in daily clinical oncology. Shedding light on the crosstalk between allergic response and cancer is paving the way for new avenues of treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 866-887 |
| Number of pages | 22 |
| Journal | Allergy: European Journal of Allergy and Clinical Immunology |
| Volume | 72 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Jun 1 2017 |
Fingerprint
Keywords
- AllergoOncology
- allergy
- atopy
- biologics, desensitization
- cancer
- chemotherapeutic
- clinical oncology
- IgE
- IgG4
- inflammation
- tumor
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Cite this
AllergoOncology – the impact of allergy in oncology : EAACI position paper. / Jensen-Jarolim, E.; Bax, H. J.; Bianchini, R.; Capron, M.; Corrigan, C.; Castells, M.; Dombrowicz, David; Daniels-Wells, T. R.; Fazekas, J.; Fiebiger, E.; Gatault, S.; Gould, H. J.; Janda, J.; Josephs, D. H.; Karagiannis, P.; Levi-Schaffer, F.; Meshcheryakova, A.; Mechtcheriakova, D.; Mekori, Y.; Mungenast, F.; Nigro, Elisa A.; Penichet, M. L.; Redegeld, F.; Saul, L.; Singer, J.; Spicer, J. F.; Siccardi, Antonio G.; Spillner, E.; Turner, M. C.; Untersmayr, E.; Vangelista, L.; Karagiannis, S. N.
In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 72, No. 6, 01.06.2017, p. 866-887.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - AllergoOncology – the impact of allergy in oncology
T2 - EAACI position paper
AU - Jensen-Jarolim, E.
AU - Bax, H. J.
AU - Bianchini, R.
AU - Capron, M.
AU - Corrigan, C.
AU - Castells, M.
AU - Dombrowicz, David
AU - Daniels-Wells, T. R.
AU - Fazekas, J.
AU - Fiebiger, E.
AU - Gatault, S.
AU - Gould, H. J.
AU - Janda, J.
AU - Josephs, D. H.
AU - Karagiannis, P.
AU - Levi-Schaffer, F.
AU - Meshcheryakova, A.
AU - Mechtcheriakova, D.
AU - Mekori, Y.
AU - Mungenast, F.
AU - Nigro, Elisa A.
AU - Penichet, M. L.
AU - Redegeld, F.
AU - Saul, L.
AU - Singer, J.
AU - Spicer, J. F.
AU - Siccardi, Antonio G.
AU - Spillner, E.
AU - Turner, M. C.
AU - Untersmayr, E.
AU - Vangelista, L.
AU - Karagiannis, S. N.
PY - 2017/6/1
Y1 - 2017/6/1
N2 - Th2 immunity and allergic immune surveillance play critical roles in host responses to pathogens, parasites and allergens. Numerous studies have reported significant links between Th2 responses and cancer, including insights into the functions of IgE antibodies and associated effector cells in both antitumour immune surveillance and therapy. The interdisciplinary field of AllergoOncology was given Task Force status by the European Academy of Allergy and Clinical Immunology in 2014. Affiliated expert groups focus on the interface between allergic responses and cancer, applied to immune surveillance, immunomodulation and the functions of IgE-mediated immune responses against cancer, to derive novel insights into more effective treatments. Coincident with rapid expansion in clinical application of cancer immunotherapies, here we review the current state-of-the-art and future translational opportunities, as well as challenges in this relatively new field. Recent developments include improved understanding of Th2 antibodies, intratumoral innate allergy effector cells and mediators, IgE-mediated tumour antigen cross-presentation by dendritic cells, as well as immunotherapeutic strategies such as vaccines and recombinant antibodies, and finally, the management of allergy in daily clinical oncology. Shedding light on the crosstalk between allergic response and cancer is paving the way for new avenues of treatment.
AB - Th2 immunity and allergic immune surveillance play critical roles in host responses to pathogens, parasites and allergens. Numerous studies have reported significant links between Th2 responses and cancer, including insights into the functions of IgE antibodies and associated effector cells in both antitumour immune surveillance and therapy. The interdisciplinary field of AllergoOncology was given Task Force status by the European Academy of Allergy and Clinical Immunology in 2014. Affiliated expert groups focus on the interface between allergic responses and cancer, applied to immune surveillance, immunomodulation and the functions of IgE-mediated immune responses against cancer, to derive novel insights into more effective treatments. Coincident with rapid expansion in clinical application of cancer immunotherapies, here we review the current state-of-the-art and future translational opportunities, as well as challenges in this relatively new field. Recent developments include improved understanding of Th2 antibodies, intratumoral innate allergy effector cells and mediators, IgE-mediated tumour antigen cross-presentation by dendritic cells, as well as immunotherapeutic strategies such as vaccines and recombinant antibodies, and finally, the management of allergy in daily clinical oncology. Shedding light on the crosstalk between allergic response and cancer is paving the way for new avenues of treatment.
KW - AllergoOncology
KW - allergy
KW - atopy
KW - biologics, desensitization
KW - cancer
KW - chemotherapeutic
KW - clinical oncology
KW - IgE
KW - IgG4
KW - inflammation
KW - tumor
UR - http://www.scopus.com/inward/record.url?scp=85010387157&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85010387157&partnerID=8YFLogxK
U2 - 10.1111/all.13119
DO - 10.1111/all.13119
M3 - Article
AN - SCOPUS:85010387157
VL - 72
SP - 866
EP - 887
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
SN - 0105-4538
IS - 6
ER -